Evogene Ltd. (EVGN) Financials

EVGN Assets vs Liabilities
DateAssetsLiabilities
June 30, 2026 13.4 million 4.5 million
March 31, 2026 17.9 million 10.0 million
Dec. 31, 2025 20.0 million 8.1 million
Sept. 30, 2025 26.1 million 8.8 million

EVGN Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 -2.1 million ?
March 31, 2026 -3.0 million -9000
Dec. 31, 2025 -2.7 million 155000
Sept. 30, 2025 -3.8 million 27000

EVGN Net Income

No data available :(

EVGN Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 9.4 million - 1.4 million
March 31, 2026 13.1 million - 2.0 million
Dec. 31, 2025 13.0 million - 2.2 million
Sept. 30, 2025 16.0 million - 2.5 million

EVGN Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 12.2 million
March 31, 2026 9.7 million
Dec. 31, 2025 8.7 million
Sept. 30, 2025 8.7 million

EVGN Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 9287 1.2 million 1.2 million -
March 31, 2026 2000 1.8 million 1.5 million 389000
Dec. 31, 2025 6000 1.8 million 1.2 million -993000
Sept. 30, 2025 11292 1.4 million 1.5 million 369000

EVGN Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 347000 355000
March 31, 2026 334000 130000
Dec. 31, 2025 314000 2.3 million
Sept. 30, 2025 312000 157000

EVGN

Price: $0.48

52 week price:
0.37
1.50

Payout Ratio Range:
-144.09%
-3.29%

Earnings Per Share: -1.75 USD

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Country: Israel

Volume: 71621

Ebitda: -8.5 million

Market Capitalization: 4.6 million

Links: